Summary
Multiple statements are broadly worded and include assertions (e.g., “no fixed maximum duration,” “stopping/restarting based on disease control”) that are not directly supported by the supplied label excerpts; the provided information is insufficient to verify key on-label dosing/continuation details.
Category Scores
Accurate Statements
Cosentyx’s labeled dosing is condition-specific.
Label provides different recommended dosages by indication (e.g., PsO 300 mg every 4 weeks after loading; HS 300 mg every 4 weeks after loading with option to increase to every 2 weeks; PsA/AS also reference PsO dosing and possible escalation).
Cosentyx dosing schedules may include starting and maintenance doses.
Label PsO dosing includes administration at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; HS similarly includes Weeks 0–4 then every 4 weeks thereafter.
Cosentyx dosing schedules may include potential adjustments based on the condition and response.
Label includes escalation considerations in PsA and AS (consider increasing to 300 mg every 4 weeks if active disease persists) and in HS (consider increasing to 300 mg every 2 weeks if inadequate response).
Unsupported Statements
For plaque psoriasis, Cosentyx is typically used continuously.
Supplied label excerpts provide dosing frequency (including continuation “every 4 weeks thereafter”) but do not explicitly state “typically used continuously.”
The prescribing information for Cosentyx describes continuing therapy as long as it is clinically needed rather than setting a single maximum duration.
No provided label excerpt states that therapy is continued “as long as it is clinically needed” or addresses absence of a maximum duration.
No fixed time limit is stated in the available prescribing information for Cosentyx.
The prompt’s label excerpts do not include a section that would establish whether a fixed maximum duration is stated or not stated.
Stopping and restarting Cosentyx are typically based on disease control and the prescriber’s judgment rather than a maximum number of months or years.
The provided excerpts do not describe stopping/restarting criteria or relate them to “disease control” or “prescriber’s judgment,” nor do they mention maximum time on therapy.
Each indication is managed as a chronic disease treatment approach.
The supplied excerpts describe dosing schedules and indications but do not explicitly characterize management as a “chronic disease treatment approach.”
The label supports ongoing use when benefits outweigh risks.
While the label includes caution/discontinuation in certain scenarios (e.g., serious infection) the supplied excerpts do not explicitly state a general “benefits outweigh risks” ongoing-use statement.
Contradictions
Important Omissions
A clear, label-grounded statement of continuation of dosing for plaque psoriasis (e.g., “every 4 weeks thereafter”) rather than general claims about “continuous” use.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Broad assertions about duration/continuation and stopping/restarting without direct excerpt support may lead to misinterpretation of on-label therapy management details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Several statements about therapy duration (continuous use, no maximum duration, and stopping/restarting criteria) are not supported by the supplied label excerpts.
Suggested Improvement
Restrict claims to label-supported dosing language (e.g., “every 4 weeks thereafter” for PsO/HS after the loading period) and avoid asserting general guidance on maximum duration, typical continuity, or stop/restart decision logic unless directly quoted from the provided label text.